Pull to refresh
Logo
Daily Brief
Following Why Sign Up
FDA authorizes first standalone robotic blood-draw device

FDA authorizes first standalone robotic blood-draw device

New Capabilities

Aletta, made by Netherlands-based Vitestro, wins US clearance to draw blood without a person guiding the needle

August 20th, 2026: Vitestro lays out US rollout plans

Overview

Updated Aug 24

A robot can now draw your blood. The FDA cleared Aletta on August 19, the first standalone device that finds a vein and takes a sample without a person guiding the needle.

Aletta uses near-infrared light and Doppler ultrasound to find a vein and rule out arteries. One trained phlebotomist oversees up to three machines at once, which matters because the US is short on phlebotomists. Vitestro, the Dutch maker, says Aletta has already handled more than 10,000 patients in Europe and plans a US clinical trial before a US launch.

Why it matters

For the first time, a routine medical procedure most Americans go through can be done by a machine, with one human supervising three at a time.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

3
Devices per supervisor
One trained phlebotomist can oversee up to three Aletta units at the same time.
10,000+
Patients treated worldwide
Vitestro says Aletta has drawn blood from more than 10,000 patients across Europe and the US, including its pre-FDA use.
$70M
Funding raised March 2026
Vitestro's Series B round, backed by Labcorp's venture arm, Mayo Clinic, Sutter Health, and Intuitive co-founder Fred Moll.
18,400
Annual US phlebotomist openings
Bureau of Labor Statistics projection of average yearly openings through 2034.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Toon Overbeeke
Toon Overbeeke
Chief Executive and co-founder, Vitestro
Leading Vitestro's planned US multicenter clinical trial and commercial rollout after FDA clearance

Organizations Involved

Vitestro
Vitestro
Medical robotics company
FDA-cleared; planning US multicenter clinical trial ahead of commercial launch

A Utrecht-based medical robotics company that built Aletta, the first FDA-authorized standalone blood-draw robot.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Authorized Aletta through the De Novo pathway

The federal agency that reviews and clears medical devices for the US market.

Timeline

January 2017 August 2026

5 events Latest: August 20th, 2026 · 3 weeks ago
Tap a bar to jump to that date

  1. Vitestro lays out US rollout plans

    Latest Corporate

    Vitestro confirms the FDA De Novo authorization and says a US multicenter clinical trial will precede commercial launch. The company names Labcorp, Mayo Clinic, and Sutter Health among the backers of its $70 million March round.

  2. FDA authorizes Aletta

    Regulatory

    The FDA clears the first standalone robotic blood-draw device through the De Novo pathway, creating a new device category.

  3. Vitestro raises $70 million

    Funding

    A larger round funds broader clinical adoption, months before the US regulatory decision.

  4. Vitestro raises $22 million

    Funding

    The company secures roughly €20 million to advance its autonomous blood-draw device and European rollout.

  5. Vitestro founded in Utrecht

    Origin

    Toon Overbeeke and Brian Joseph start Vitestro to automate diagnostic blood collection.

Scenarios

1

Aletta starts drawing blood in a US clinic

Likely Resolves by End of 2027

Discussed by: MedTech Dive, Clinical Lab Products, Vitestro

With clearance in hand, Vitestro moves from approval to real patients. A US hospital, lab, or clinic network announces it is using Aletta on patients in routine practice. This follows the pattern the company set in Europe, where CE certification led to a commercial rollout. The gating factors are manufacturing, pricing, and finding early adopters willing to put a robot in front of patients.

2

A rival wins its own FDA nod for an autonomous blood-draw robot

Uncertain Resolves by Aug 19, 2028

Discussed by: Citeline Medtech Insight, industry analysts

The De Novo authorization sets the criteria a second entrant would be measured against, which usually lowers the barrier for the next device. A competing company could seek and win FDA clearance for its own autonomous blood-draw system, turning a single-product milestone into a category. No named challenger has a public FDA submission yet, which makes the timing uncertain.

3

Safety problem triggers an FDA recall or warning

Unlikely Resolves by Aug 19, 2028

Discussed by: FDA safety reporting, patient-safety researchers

The device has safeguards, including a needle that detaches if a patient moves too much. But autonomous procedures on real patients can surface problems that trials miss. A reported injury pattern, a correction, or a recall would slow adoption and shape how regulators treat the whole category. This is the downside case that early adopters weigh against the labor savings.

4

Labcorp rolls out Aletta across US draw stations

Possible Resolves by End of 2027

Discussed by: MedTech Dive, Vitestro funding disclosure

Labcorp's venture arm invested in Vitestro's $70 million March round, and Labcorp employs thousands of phlebotomists. If Labcorp adopts Aletta in its patient service centers, that would be the largest single US deployment and a strong signal for the category. Timing depends on the US multicenter trial and product pricing.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

July 2000

FDA clears the da Vinci Surgical System (2000)

The FDA cleared Intuitive Surgical's da Vinci system, letting surgeons operate through a robotic console instead of directly by hand. It was the first robotic system cleared for general soft-tissue surgery in the United States.

Then

Adoption was slow at first, limited by cost and surgeon training.

Now

Robotic surgery became routine for many procedures, and da Vinci systems are now in thousands of hospitals worldwide.

Why this matters now

It shows the usual arc for a first-of-its-kind clinical robot: clearance is the start, and real adoption takes years of training, pricing, and trust-building.

2015-2018

Theranos collapses over false blood-test claims (2015-2018)

Theranos claimed it could run hundreds of tests from a finger-prick of blood. Reporting and regulators found the technology did not work, and founder Elizabeth Holmes was later convicted of fraud.

Then

The company voided years of test results and shut down.

Now

It left lasting skepticism toward startups promising to reinvent blood testing.

Why this matters now

It is the cautionary contrast: Theranos avoided regulatory validation, while Aletta cleared the FDA on clinical data it can point to. The comparison is why FDA review matters here.

April 2018

FDA authorizes IDx-DR autonomous AI diagnostic (2018)

The FDA permitted marketing of IDx-DR, the first artificial-intelligence system cleared to make a medical diagnosis on its own. It screens for diabetic retinopathy from eye images without a doctor reading the result.

Then

It let primary-care clinics screen for the disease without an eye specialist on site.

Now

It set an early template for how the FDA reviews autonomous systems that act without a clinician in the loop.

Why this matters now

Like Aletta, it cleared the De Novo pathway and removed the human from a step long assumed to need one, raising the same questions about oversight and liability.

Sources

(9)
+3
U.S. Food and Drug Administration GlobeNewswire Clinical Lab Products MedTech Dive Citeline Medtech Insight Vitestro U.S. Bureau of Labor Statistics Medical Xpress Vitestro